E8 Pharmaceuticals, LLC and the Massachusetts Institute of Technology v. Affymetrix, Inc. and Navigenics, Inc.

N OTE: This disposition is nonprecedential.
United States Court of Appeals
for the Federal Circuit
______________________
E8 PHARMACEUTICALS, LLC AND THE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY,
Plaintiffs-Appellants,
v.
AFFYMETRIX, INC. AND NAVIGENICS, INC.,
Defendants-Appellees.
______________________
2013-1046
______________________
Appeal from the United States District Court for the
District of Massachusetts in consolidated No. 08-CV-
11132, Judge George A. O'Toole, Jr.
______________________
Decided: November 6, 2013
______________________
J OHN B. WYSS , Wiley Rein LLP, of Washington, DC,
argued for plaintiffs-appellants. With him on the brief
were J AMES H. WALLACE , J R., MARK A. P ACELLA , and
G REGORY R. L YONS .
P ETER E. ROOT , Kaye Scholer LLP, of Palo Alto, Cali-
fornia, argued for defendants-appellees. With him on the
brief were MICHAEL J. MALECEK, SEAN M. BOYLE, and
G ARY ROSS ALLEN.

-- 1 of 2 --

E8 PHARMACEUTICALS, LLC v. AFFYMETRIX , INC. 2
______________________
Before L OURIE, D YK, and O’MALLEY , Circuit Judges.
P ER CURIAM .
We affirm the judgment of noninfringement in favor
of Affymetrix, Inc. and Navigenics, Inc. We base our
decision solely on our agreement with the district court’s
construction of the phrase “randomly primed PCR-derived
RCG.” We do not reach any other issues raised on appeal.
AFFIRMED

-- 2 of 2 --